As November 21st marks World Pancreatic Cancer Day, Oxford clinicians and scientists are uniting in the fight against the world’s toughest cancer. To launch this, Oxford clinicians and scientists met for the first Oxford Pancreatic Network meeting on Tuesday 19th November, organised by Dr Rachael Bashford-Rogers (WTCHG) and Dr Shivan Sivakumar (Oncology, KIR and pancreatic cancer oncologist) in collaboration with the CRUK Cancer Oxford Centre.
Pancreatic cancer has the worst survival of any human cancer. This is a tumour that has minimal response to conventional treatment and is extremely aggressive. The disease course is silent and is picked up mainly when incurable. To tackle this clinical need, we are bringing together experimental, clinical and statistical expertise from Oxford’s scientific community to investigate the microenvironment across multiple pancreatic pathologies and to plan new approaches to treatment strategies for improving patient outcome.
This pioneering proposal of the study of cause and effect of pancreatic disease, ranging from pancreatic cancer and pre-cancerous lesions to pancreatitis, immune-related diseases, type 1 and 2 diabetes, will be achieved through the integration of state-of-the-art technologies, underpinned by strong bioinformatics and functional studies. The aim of the work is to truly understand the pancreas and how it causes such significant but varying diseases. Helping us understand this may truly help us unlock the potential to treat pancreatic cancer.
This work will use knowledge gained from cross-pancreatic diseases to:
• understand which cells are able to enter the pancreatic micro-environment and their functions
• the modes of anti-tumour/auto-reactive activity
• strategies for early detection
• effect of current therapies/toxicities
• develop models of how to modulate the function and pancreatic infiltration of cells
• to direct us towards more targeted therapies across pancreatic diseases, such as through novel immunotherapies, and developing new clinical trials
Through this new partnership of expertise, we aim to build a new strategy to make an impact in the treatment of these pancreatic diseases.